title: Successful third kidney transplantation with intensive immunosuppression in a highly sensitized recipient.
abstract: HLA sensitization associated with previous kidney transplantation is a major drawback to retransplantation. Recently we successfully performed a third graft using intensive immunosuppression for a highly sensitized recipient. The patient was a 31-year-old man who had previously undergone a living donor graft from his father at our institute in 1999. His kidney graft function had deteriorated due to chronic allograft nephropathy, returning to hemodialysis therapy in 2005. He received a second graft from a deceased donor in another country on August 14, 2006. It rejected on postoperative day 3 possibly due to acute accelerated rejection. He was offered a third kidney from his brother. Panel-reactive antibody (PRA) tested before the third procedure revealed positive class I (88%) and class II (96%) PRAs. Mycophenolate mofetil (MMF) was started 3 weeks before the third transplantation, and preoperative plasmapheresis performed thrice. He underwent the living donor graft on March 9, 2007. Immunosuppression consisted of tacrolimus, MMF, methylprednisolone, and basiliximab. Immediately afterward there was a sudden decrease in allograft blood flow and urine output, implying hyperacute rejection. Following treatment with plasmapheresis and a single dose of rituximab (200 mg), the kidney allograft function recovered, although the PRA at 3 weeks was still positive. Six months posttransplantation, he is well with a creatinine of 0.9 mg/dL. Our protocol may reduce the risk for graft loss in a highly sensitized transplant recipient.
authors.affiliation: Department of Surgery, Kidney Center, Itabashi Chuo General Hospital, Tokyo, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Kawase
authors.forename: T
authors.initials: T
authors.lastname: Tojimbara
authors.forename: R
authors.initials: R
authors.lastname: Niki
authors.forename: M
authors.initials: M
authors.lastname: Akamatsu
authors.forename: I
authors.initials: I
authors.lastname: Nakajima
authors.forename: S
authors.initials: S
authors.lastname: Fuchinoue
authors.forename: T
authors.initials: T
authors.lastname: Agishi
authors.forename: S
authors.initials: S
authors.lastname: Teraoka
mesh_terms: D000328:Adult; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000276:immunology; D006801:Humans; D007114:Immunization; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology; D008297:Male; D012086:Reoperation / Q000706:statistics & numerical data*
chemical_list: D007166:Immunosuppressive Agents